[Skip to Navigation]
November 1959

Treatment of Pleural and Peritoneal Effusion with Intracavitary Colloidal Radiogold (Au 198)

Author Affiliations

Nashville, Tenn.

Department of Medicine and the Radioisotope Center, Vanderbilt University School of Medicine.; Rockefeller Foundation Research Fellow, Gdansk, Poland (Dr. Dybicki). Assistant Professor of Medicine, University of Southern California School of Medicine, Los Angeles (Dr. Balchum). Associate Professor of Medicine and Director of the Radioisotope Center, Vanderbilt University School of Medicine and Hospital, Nashville, Tenn. (Dr. Meneely).

AMA Arch Intern Med. 1959;104(5):802-815. doi:10.1001/archinte.1959.00270110122017

Therapy for recurrent effusions of the pleural and peritoneal cavities of patients with local or metastatic malignant processes is an important and often difficult clinical problem. Such effusions occur in at least 29% 1 of such patients, and, if recurrent and large, they can be the most significant factor in their management. Repeated withdrawals of abdominal and pleural fluid are not only trying to the patient but result in depletion of electrolytes and proteins. The intracavitary instillation of radioactive colloidal gold (Au198) is frequently of distinct benefit in slowing down or halting the accumulation of fluid, even though such therapy is not curative and does not abolish the malignant process.

An artificially induced radioactive isotope in colloid form was administered for therapeutic purposes for the first time in 1944, in Vanderbilt University Hospital. This was molecular iodine colloid made with cyclotron-produced I130 and prepared by Paul F. Hahn.

Add or change institution